Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families
- PMID: 27025497
- DOI: 10.1007/s12282-016-0693-4
Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families
Abstract
Background: With the increasing request for BRCA1/BRCA2 mutation tests, several risk models have been developed to predict the presence of mutation in these genes; in this study, we have developed an efficient BRCA genetic testing strategy.
Method: As first step, to identify predictor variables associated with BRCA status, we have undertaken a cumulative mutation analysis including data from three Tunisian studies. Then, we have developed a logistic regression model for predicting the likelihood of harboring a BRCA mutation. Using receiver operating characteristic curves (ROC), an effective evaluation was performed. A total of 92 Tunisian families were included. Overall, 27 women were positive for BRCA1/BRCA2 deleterious mutations.
Results: Tow recurrent mutations (c.211dupA and c.5266dupC) explained 76 % of BRCA1-related families and three recurrent mutations (c.1310_1313del, c.1542_1547delAAGA and c.7887_7888insA) explained 90 % of BRCA2-related families. Early age at diagnosis of breast cancer, ovarian cancer, bilateral breast cancer were associated with BRCA1, whereas male breast cancer and four or more breast cancer cases in the family were associated with BRCA2. The area under the receiver operating characteristic curve of the risk score was 0.802 (95 % confidence interval = 0.0699-0. 905).
Conclusion: Logistic regression reported particular profiles related to BRCA germline mutation carriers in our population, as well as an efficient prediction model that may be a useful tool for increasing the cost-effectiveness of genetic testing strategy.
Keywords: BRCA predictive models; BRCA1; BRCA2; Breast cancer; Predictive factors.
Similar articles
-
Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.Clin Genet. 2015 Feb;87(2):155-60. doi: 10.1111/cge.12337. Epub 2014 Feb 23. Clin Genet. 2015. PMID: 24372583
-
Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.Clin Genet. 2006 Oct;70(4):320-9. doi: 10.1111/j.1399-0004.2006.00673.x. Clin Genet. 2006. PMID: 16965326
-
Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.Cancer Genet. 2017 Jan;210:22-27. doi: 10.1016/j.cancergen.2016.11.002. Epub 2016 Nov 18. Cancer Genet. 2017. PMID: 28212807
-
Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.BMC Cancer. 2022 Feb 25;22(1):208. doi: 10.1186/s12885-022-09181-4. BMC Cancer. 2022. PMID: 35216584 Free PMC article.
-
BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.Fam Cancer. 2006;5(1):15-20. doi: 10.1007/s10689-005-2571-7. Fam Cancer. 2006. PMID: 16528604 Review.
Cited by
-
Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.DNA Repair (Amst). 2023 Oct;130:103563. doi: 10.1016/j.dnarep.2023.103563. Epub 2023 Aug 19. DNA Repair (Amst). 2023. PMID: 37651978 Free PMC article. Review.
-
Identification of novel candidate genes by exome sequencing in Tunisian familial male breast cancer patients.Mol Biol Rep. 2020 Sep;47(9):6507-6516. doi: 10.1007/s11033-020-05703-0. Epub 2020 Sep 8. Mol Biol Rep. 2020. PMID: 32901360
-
Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.BMC Cancer. 2019 Mar 21;19(1):256. doi: 10.1186/s12885-019-5463-1. BMC Cancer. 2019. PMID: 30898109 Free PMC article.
-
Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.Breast Cancer Res Treat. 2022 Jul;194(1):187-198. doi: 10.1007/s10549-022-06622-3. Epub 2022 May 17. Breast Cancer Res Treat. 2022. PMID: 35578052
-
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.J Transl Med. 2019 Apr 11;17(1):123. doi: 10.1186/s12967-019-1873-8. J Transl Med. 2019. PMID: 30975216 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous